Lisa M. Krieger, The Mercury News; Coronavirus: The global race to patent a remedy
"As a lethal coronavirus triggers a humanitarian crisis in the world’s
most populous nation, who owns the rights to a potential cure?
The Bay Area’s pharmaceutical powerhouse Gilead Sciences is first in
line for a Chinese patent for its drug called Remdesivir, which shows
promise against the broad family of coronaviruses.
But now a team of Chinese scientists say they’ve improved and
targeted its use — and, in a startling move, have also filed for a
patent...
“Each side wants to be the entity that came up with the treatment for
coronavirus,” said Jacob Sherkow, professor of law at the Innovation
Center for Law and Technology at New York Law School. “This is not a
knockoff of a Louis Vuitton handbag,”...
Patent protection — and market exclusivity — is the lifeblood of drug
companies such as Gilead, creating the incentive to find, test and
market a medicine."
Showing posts with label incentives for finding testing marketing medicines. Show all posts
Showing posts with label incentives for finding testing marketing medicines. Show all posts
Friday, February 14, 2020
Subscribe to:
Posts (Atom)